(Q74823202)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10147042%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

title

Economic evaluation of pharmaceuticals: a critical appraisal of seven studies on cholesterol-lowering agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10147042%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

author name string

P Gazzaniga

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10147042%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

L Garattini

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10147042%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

publication date

1 October 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10147042%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10147042%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10147042%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10147042%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

page(s)

270-278

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10147042%20AND%20SRC:MED&resulttype=core&format=json

Should there be a moratorium on the use of cholesterol lowering drugs?

13 November 2019

cites work

1 reference

12 December 2020

QALYs: are they enough? A health economist's perspective

1 reference

12 December 2020

Introduction: lipids and coronary disease--resolved and unresolved problems

1 reference

12 December 2020

Quality of life instruments in the evaluation of new drugs

1 reference

12 December 2020

Economic evaluation of pharmaceuticals: science or marketing?

1 reference

12 December 2020

1 reference

12 December 2020

Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands

1 reference

12 December 2020

Medical costs of coronary artery disease in the United States.

1 reference

12 December 2020

Clinical economics. A guide to the economic analysis of clinical practices

1 reference

12 December 2020

Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate?

1 reference

12 December 2020

An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction

1 reference

12 December 2020

Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease

1 reference

12 December 2020

Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals

1 reference

12 December 2020

Principles of pharmacoeconomic analysis of drug therapy

1 reference

12 December 2020

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

1 reference

12 December 2020

Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management

1 reference

12 December 2020

Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

1 reference

12 December 2020

Use and misuse of the term "cost effective" in medicine

1 reference

12 December 2020

Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine

1 reference

12 December 2020

Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia

1 reference

12 December 2020